封面
市场调查报告书
商品编码
1611965

无细胞疗法市场:按框架和应用划分-2025年至2030年全球预测

Acellular Therapy Market by Scaffold (Cell Laden Hydrogel, Extracellular Matrix (ECM), Fused Deposition Modeling (FDM)), Application (Cardiology, Gastroenterology, Hepatology) - Global Forecast 2025-2030

出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

无细胞治疗市场2023年估值为110.7亿美元,预计2024年将达到124.9亿美元,复合年增长率为13.37%,到2030年将达到266.5亿美元。

无细胞疗法是再生医学的前沿领域,利用细胞外基质、生长因子和细胞激素等无细胞成分来促进组织修復和再生。无细胞疗法的需求源于解决传统细胞疗法带来免疫风险或不切实际的疾病状态的潜力。其应用范围从创伤治疗和整形外科修復到心血管和神经治疗。主要的最终用途领域包括医院、研究机构和门诊手术中心。市场成长的主要驱动力是技术进步、意识提高和慢性病的增加。个人化医疗方法以及透过奈米技术整合细胞成分以增强递送和功效的机会比比皆是。公司可以透过投资研发合作伙伴关係和研究合作来利用这些趋势,旨在开发针对特定医疗条件的解决方案。

主要市场统计
基准年[2023] 110.7亿美元
预计年份 [2024] 124.9亿美元
预测年份 [2030] 266.5亿美元
复合年增长率(%) 13.37%

然而,一些挑战正在影响市场的成长。监管障碍仍然是一个主要问题,因为细胞培养疗法有时需要更广泛的检验和标准化流程。人们对长期疗效有一些怀疑,需要全面的临床测试和资料来获得相关人员的信心。此外,与研发相关的高成本以及製造的复杂性可能会阻止新进入者并影响整体市场竞争。

创新的最佳途径是开发能够模仿自然组织环境并与人体生理学更好地融合的新型生物材料。专注于提高细胞成分在储存和运输过程中的稳定性和生物活性的研究部分对于传播至关重要。了解市场动态表明,北美和欧洲由于其发达的医疗基础设施而具有主导成长轨迹,而亚太地区由于医疗投资的增加而具有更大的潜力。企业应专注于透过伙伴关係关係制定适应性策略,并开拓开拓的区域市场,以在不断变化的环境中保持竞争力。

市场动态:揭示快速发展的无细胞治疗市场的关键市场洞察

无细胞治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态,公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险,并了解消费行为及其对製造成本的影响,并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 慢性病和与老龄化相关的疾病盛行率增加
    • 政府推动再生医学和干细胞研究的倡议
    • 增加无细胞和智慧生物材料的可用性
  • 市场限制因素
    • 缺乏熟练的研究人员和有限的报销选择
  • 市场机会
    • 全球无细胞疗法进展及研发
    • 本院及医疗机构无细胞治疗计划增多
  • 市场问题
    • 有关再生医学和细胞治疗的复杂法规

波特五力:驾驭无细胞治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势,解决弱点并避免潜在的挑战,从而确保更强大的市场地位。

PESTLE分析:了解对无细胞治疗市场的外部影响

外部宏观环境因素在塑造非细胞治疗市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素,公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化,并帮助他们做出积极主动的决策。

市场占有率分析:了解无细胞治疗市场的竞争格局

对无细胞治疗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势,为供应商提供了製定策略决策所需的洞察力,使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵:无细胞治疗市场供应商的绩效评估

FPNV定位矩阵是评估无细胞治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商,从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商,并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议:绘製无细胞治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说,对无细胞治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标,公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战,利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率:对当前市场环境的详细审查,主要企业的广泛资料,评估他们在市场中的影响力和整体影响力。

2. 市场开拓:辨识新兴市场的成长机会,评估现有细分市场的扩张潜力,并提供未来成长的策略蓝图。

3. 市场多元化:分析近期产品发布、开拓地区、主要产业进展、塑造市场的策略投资。

4. 竞争评估与情报:彻底分析竞争格局,检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新:重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题,以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少?

2. 哪些产品和地区提供最佳投资机会?

3.塑造市场的关键技术趋势和监管影响是什么?

4.主要厂商的市场占有率和竞争地位如何?

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么?

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病和与老龄化相关的疾病增加
      • 政府推动再生医学和干细胞研究的倡议
      • 提高无细胞和智慧生物材料的可用性
    • 抑制因素
      • 缺乏熟练的研究人员和有限的报销选择
    • 机会
      • 全球无细胞疗法的进展与研发
      • 医院和医疗机构实施的无细胞治疗计划增加
    • 任务
      • 有关再生医学和无细胞疗法的复杂法规
  • 市场区隔分析
    • 骨骼:细胞外基质支持的优先非细胞治疗
    • 应用:开发肿瘤学中针对肿瘤部位的无细胞疗法
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章无细胞治疗市场:透过支架

  • 介绍
  • 含细胞水凝胶
  • 细胞外基质(ECM)
  • 熔融沈积建模 (FDM)

第七章无细胞治疗市场:依应用分类

  • 介绍
  • 心臟病学
  • 胃肠病学
  • 肝病学
  • 神经病学
  • 肿瘤学

第八章美洲无细胞治疗市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太无细胞治疗市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲的无细胞治疗市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵,2023
  • 竞争情境分析
    • Humacyte 宣布人类无细胞血管 (HAV) 治疗血管创伤患者的 2/3 期试验取得正面结果
    • FDA核准细胞疗法 Lantidra 用于治疗第 1 型糖尿病
    • Humacyte 向乌克兰前线医院提供人类去细胞血管(HAV),用于治疗血管创伤
  • 战略分析和建议

公司名单

  • Allergan Inc. by Abbvie Inc.
  • AlloSource
  • Aziyo Biologics
  • Baxter International
  • Becton, Dickinson and Company
  • BioHorizons, Inc.
  • EnColl Corporation
  • Engitix Ltd
  • Fidia Farmaceutici SpA
  • GSK PLC
  • Humacyte, Inc.
  • In2Bones Global by CONMED Corporation
  • Integra LifeSciences Corporation
  • LifeNet Health
  • MiMedx Group
  • Organicell Regenerative Medicine, Inc.
  • Organogenesis Holdings Inc.
  • Reprise Biomedical, Inc.
  • Sanofi SA
  • Smith & Nephew PLC
  • Stryker Corporation
  • Tissue Regenix
  • Vascudyne, Inc.
  • Zimmer Biomet
Product Code: MRR-5A3042B3D68D

The Acellular Therapy Market was valued at USD 11.07 billion in 2023, expected to reach USD 12.49 billion in 2024, and is projected to grow at a CAGR of 13.37%, to USD 26.65 billion by 2030.

Acellular therapy, a cutting-edge segment within regenerative medicine, involves using cell-free components such as extracellular matrix, growth factors, and cytokines to promote tissue repair and regeneration. The necessity for acellular therapy arises from its potential to address conditions where traditional cellular therapies may introduce immunological risks or be impractical. Applications are vast, ranging from wound healing and orthopedic repairs to cardiovascular and neurological therapy. Key end-use segments include hospitals, research institutes, and ambulatory surgical centers. Market growth is largely driven by technological advancements, increasing awareness, and a rise in chronic disease prevalence. Opportunities abound in personalized medicine approaches and integrating acellular components with nanotechnology for enhanced delivery and efficacy. Companies can capitalize on these trends by investing in R&D partnerships and collaborations aimed at developing tailored solutions for specific medical conditions.

KEY MARKET STATISTICS
Base Year [2023] USD 11.07 billion
Estimated Year [2024] USD 12.49 billion
Forecast Year [2030] USD 26.65 billion
CAGR (%) 13.37%

However, several challenges affect market progression. Regulatory hurdles remain a significant concern as acellular therapies, in some cases, need more extensive validation and standardization processes. Skepticism exists around long-term efficacy, pushing the need for comprehensive clinical trials and data to gain stakeholder confidence. Additionally, high costs associated with R&D, alongside manufacturing complexities, can hinder entry for new players, affecting overall market competition.

Innovations are best pursued in the development of novel biomaterials that can mimic natural tissue environments and achieve better integration with human physiology. Research areas focusing on improving the stability and bioactivity of acellular components during storage and transport will be critical for widespread implementation. Understanding market dynamics reveals a growth trajectory dominated by North America and Europe due to their developed healthcare infrastructure, while Asia-Pacific shows immense potential due to increasing healthcare investments. Businesses should focus on building adaptive strategies leveraging partnerships and exploring untapped regional markets to maintain a competitive edge in this evolving landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Acellular Therapy Market

The Acellular Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of chronic diseases and age-related conditions
    • Government initiatives to propel regenerative medicine and stem cell research
    • Increased availability of acellular and smart biomaterials
  • Market Restraints
    • Lack of skilled research personnel and limited reimbursement options
  • Market Opportunities
    • Advancements and R&D in acellular therapy worldwide
    • Rising number of acellular therapy projects undertaken by hospitals and medical entities
  • Market Challenges
    • Complex regulations pertaining to regenerative medicine and acellular therapies

Porter's Five Forces: A Strategic Tool for Navigating the Acellular Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Acellular Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Acellular Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Acellular Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Acellular Therapy Market

A detailed market share analysis in the Acellular Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Acellular Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Acellular Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Acellular Therapy Market

A strategic analysis of the Acellular Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Acellular Therapy Market, highlighting leading vendors and their innovative profiles. These include Allergan Inc. by Abbvie Inc., AlloSource, Aziyo Biologics, Baxter International, Becton, Dickinson and Company, BioHorizons, Inc., EnColl Corporation, Engitix Ltd, Fidia Farmaceutici S.p.A, GSK PLC, Humacyte, Inc., In2Bones Global by CONMED Corporation, Integra LifeSciences Corporation, LifeNet Health, MiMedx Group, Organicell Regenerative Medicine, Inc., Organogenesis Holdings Inc., Reprise Biomedical, Inc., Sanofi S.A., Smith & Nephew PLC, Stryker Corporation, Tissue Regenix, Vascudyne, Inc., and Zimmer Biomet.

Market Segmentation & Coverage

This research report categorizes the Acellular Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Scaffold, market is studied across Cell Laden Hydrogel, Extracellular Matrix (ECM), and Fused Deposition Modeling (FDM).
  • Based on Application, market is studied across Cardiology, Gastroenterology, Hepatology, Neurology, and Oncology.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of chronic diseases and age-related conditions
      • 5.1.1.2. Government initiatives to propel regenerative medicine and stem cell research
      • 5.1.1.3. Increased availability of acellular and smart biomaterials
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of skilled research personnel and limited reimbursement options
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements and R&D in acellular therapy worldwide
      • 5.1.3.2. Rising number of acellular therapy projects undertaken by hospitals and medical entities
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulations pertaining to regenerative medicine and acellular therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Scaffold: Preference for extracellular matrix to support acellular therapy
    • 5.2.2. Application: Development of acellular therapy designed to target oncology tumor sites
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Acellular Therapy Market, by Scaffold

  • 6.1. Introduction
  • 6.2. Cell Laden Hydrogel
  • 6.3. Extracellular Matrix (ECM)
  • 6.4. Fused Deposition Modeling (FDM)

7. Acellular Therapy Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiology
  • 7.3. Gastroenterology
  • 7.4. Hepatology
  • 7.5. Neurology
  • 7.6. Oncology

8. Americas Acellular Therapy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Acellular Therapy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Acellular Therapy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Humacyte Announces Positive Top-Line Results from Phase 2/3 Trial of Human Acellular Vessel (HAV) in Treatment of Patients with Vascular Trauma
    • 11.3.2. FDA Approves Lantidra, a Cellular Therapy for Type 1 Diabetes
    • 11.3.3. Humacyte to Provide Human Acellular Vessels (HAVs) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Allergan Inc. by Abbvie Inc.
  • 2. AlloSource
  • 3. Aziyo Biologics
  • 4. Baxter International
  • 5. Becton, Dickinson and Company
  • 6. BioHorizons, Inc.
  • 7. EnColl Corporation
  • 8. Engitix Ltd
  • 9. Fidia Farmaceutici S.p.A
  • 10. GSK PLC
  • 11. Humacyte, Inc.
  • 12. In2Bones Global by CONMED Corporation
  • 13. Integra LifeSciences Corporation
  • 14. LifeNet Health
  • 15. MiMedx Group
  • 16. Organicell Regenerative Medicine, Inc.
  • 17. Organogenesis Holdings Inc.
  • 18. Reprise Biomedical, Inc.
  • 19. Sanofi S.A.
  • 20. Smith & Nephew PLC
  • 21. Stryker Corporation
  • 22. Tissue Regenix
  • 23. Vascudyne, Inc.
  • 24. Zimmer Biomet

LIST OF FIGURES

  • FIGURE 1. ACELLULAR THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. ACELLULAR THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACELLULAR THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ACELLULAR THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ACELLULAR THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACELLULAR THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACELLULAR THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ACELLULAR THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY CELL LADEN HYDROGEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY EXTRACELLULAR MATRIX (ECM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY FUSED DEPOSITION MODELING (FDM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY HEPATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ACELLULAR THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 104. ACELLULAR THERAPY MARKET, FPNV POSITIONING MATRIX, 2023